Calithera Biosciences to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019
04. November 2019 08:00 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small...
Calithera Biosciences Completes Patient Enrollment in Randomized CANTATA Trial of Telaglenastat and Cabozantinib in Advanced Renal Cell Carcinoma
03. Oktober 2019 07:05 ET
|
Calithera Biosciences, Inc.
-Top-line results expected in second half of 2020- SOUTH SAN FRANCISCO, Calif., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company...
Calithera Announces Acceptance of Two Abstracts for Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
01. Oktober 2019 16:05 ET
|
Calithera Biosciences, Inc.
First preclinical data for newly-announced IL4I1 immuno-oncology programPreclinical data for orally bioavailable CD73 inhibitor CB-708 SOUTH SAN FRANCISCO, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) --...
New Data Presented at ESMO Congress 2019 from the Arginase Inhibitor INCB001158 Alone and in Combination with Pembrolizumab
29. September 2019 10:30 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 29, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small...
Data From Randomized Phase 2 ENTRATA Study Demonstrate Telaglenastat with Everolimus Improves Progression-Free Survival in Renal Cell Carcinoma
28. September 2019 02:30 ET
|
Calithera Biosciences, Inc.
Data shared today in oral presentation at ESMO Congress 2019 show telaglenastat doubles median progression-free survival (PFS) in heavily pre-treated patients with advanced disease, reduced risk of...
Calithera to Host Webcast Conference Call for Analysts and Investors During European Society for Medical Oncology (ESMO) Congress 2019
26. September 2019 18:05 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small...
Calithera to Present at the 2019 Cantor Global Healthcare Conference
25. September 2019 08:05 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small...
Calithera Biosciences to Present New Data on Two Oncology Programs at ESMO Congress 2019
03. September 2019 09:00 ET
|
Calithera Biosciences, Inc.
-Results from ENTRATA Phase 2 trial of telaglenastat in patients with advanced renal cell carcinoma (RCC) accepted as Late Breaking Oral Presentation- -Data from INCB001158 clinical program accepted...
Calithera to Participate in Wells Fargo Healthcare Conference and Citi 14th Annual Biotech Conference
28. August 2019 08:00 ET
|
Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small...
Calithera Biosciences Reports Second Quarter 2019 Financial Results and Recent Highlights
08. August 2019 16:05 ET
|
Calithera Biosciences, Inc.
--Calithera to Provide Corporate Update via Conference Call and Webcast at 2:00 p.m. PT on August 8, 2019-- SOUTH SAN FRANCISCO, Calif., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences,...